Oasmia Pharmaceutical

About Oasmia Pharmaceutical

In 1999, founders Julian Aleksov and Bo Cederstrand started Oasmia Pharmaceutical in Sweden as a research project. Their goal was to develop better cancer treatments with fewer side effects. The core of their work was a proprietary technology platform, XR-17, designed to improve the solubility of established cancer drugs, making them more effective. The company focused on both human and veterinary oncology, developing treatments for animals alongside those for people. A key moment arrived in October 2015 when Oasmia held an Initial Public Offering (IPO) on the U.S. NASDAQ exchange. The company aimed to raise funds for new clinical trials and to expand its U.S. presence. This followed its initial listings on European exchanges, including Nasdaq Stockholm. The IPO was a significant step, although it raised less than initially planned, providing capital to advance its pipeline, which included products like Paccal Vet for animals and Apealea for ovarian cancer in humans. After years of development, clinical trials, and navigating partnerships, the company underwent a major strategic shift. In March 2022, Oasmia Pharmaceutical officially changed its name to Vivesto AB. This change marked the end of a turnaround period and reflected a renewed commitment to improving survival and quality of life for cancer patients through a focused strategy on R&D and innovation. Today, as Vivesto, the company continues its mission to develop therapies for hard-to-treat cancers, signaling a new chapter in its long journey.